newsfilter
← Earnings
Earnings Releases·

Fate Therapeutics — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Total operating expenses decreased to $32.2 million in Q3 2026 from $36.5 million in Q3 2025, driving a net loss reduction to $30.7 million ($0.25/share) from $32.3 million ($0.27/share); cash and investments stood at $139.1 million as of September 30, 2026.
  • **Cash Runway & Funding:** Cash runway extends to mid-2028, supported by current liquidity and a newly awarded $15.0 million CIRM grant for the RECLAIM-LN program.
  • **Clinical Progress:** The COMPLETE trial (FT839) is on track to dose patients by year-end 2026, while the RECLAIM-LN (FT819) Phase 2 trial is enrolling across 17 sites using a fludarabine-free conditioning regimen.
  • **Strategic Updates:** Jamie Harrell appointed to lead commercial strategy; the company highlighted strong rheumatology community enthusiasm and plans to present four abstracts at ACR Convergence 2026.
Company
FATE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology